The advent of JAK inhibitors (JAKi) inaugurated a novel era in the treatment of myelofibrosis (MF), a myeloproliferative neoplasm with heterogeneous clinical manifestations. Four JAKi have been approved for intermediate or high-risk MF, in the US. Regulatory approval of the first JAK1/2 inhibitor, ruxolitinib, in 2011 transformed the landscape of MF by markedly controlling splenomegaly and constitutional symptoms, improving patients' lives, and prolonging survival. Fedratinib, the second approved JAKi, is preferred in the second-line setting. Ruxolitinib and fedratinib can cause myelosuppression and are recommended for patients with myeloproliferative MF. Approval of 2 less myelosuppressive JAKi, pacritinib and momelotinib, provided essential treatment options for patients with severe thrombocytopenia and anemia, respectively. Pacritinib and momelotinib are potent ACVR1 inhibitors, resulting in significant anemia benefits. Transfusion independence was achieved with momelotinib in severely anemic patients, and association of transfusion independence with prolonged overall survival was demonstrated. Judicious treatment decisions of JAKi can be made with in-depth understanding of the pivotal clinical trials on JAKi and their therapeutic attributes and should be guided by the dominant clinical manifestations and the type/degree of cytopenia(s). This article reviews our clinical approach to treatment with JAKi and their sequencing in MF patients by presenting 3 clinical vignettes.
Skip Nav Destination
Review Article|
October 2, 2024
How I individualize selection of JAK inhibitors for patients with myelofibrosis
Lucia Masarova,
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
* Corresponding Author; email: [email protected]
Search for other works by this author on:
Helen T Chifotides, Dr.
Helen T Chifotides, Dr.
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Search for other works by this author on:
Blood blood.2023022415.
Article history
Submitted:
February 7, 2024
Revision Received:
September 16, 2024
Accepted:
September 19, 2024
Citation
Lucia Masarova, Helen T Chifotides; How I individualize selection of JAK inhibitors for patients with myelofibrosis. Blood 2024; blood.2023022415. doi: https://doi.org/10.1182/blood.2023022415
Download citation file:
My Account
Sign InAdvertisement intended for health care professionals
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal